^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Pancreatic Cancer
    Drug:setidegrasib (ASP3082) (KRAS G12D degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-NCI-EORTC 2022
    Title:

    ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models

    Published date:
    10/12/2022
    Excerpt:
    ...ASP3082 showed the growth inhibitory activity of KRAS G12D-mutated pancreatic cancer cells, but not of KRAS wildtype cancer cells.